Document Classification

Section Type: RESULTS

Text: Comparing MOPPEBVCAD vs. MOPPEBVCyED, the results were as follows : complete remissions 35/35 vs. 30/32 (plus one partial remission and one disease progression) ; relapses 5 vs. 8 ; deaths 2 (one of myelodysplasia) vs. 2 ; delivered mean dose intensity (DI) : lomustine 0. 79 + / -0. 67 vs. cyclophosphamide 0. 82 + / -0. 32 ; melphalan 0. 80 + / -0. 13 vs. etoposide 0. 86 + / -0. 18 ; average DI of the 7 drugs common to both regimens 0. 73 + / -0. 10 vs. 0. 83 + / -0. 11 ; all 9 drugs 0. 75 + / -0. 13 vs. 0. 84 + / -0. 09 (p = 0. 002) ; projected 5-year failure-free survival 0. 79 vs 0. 62 ; second cancers, two myelodysplasias vs. one carcinoma of the kidney.